Price to Earnings (P/E)
since 2012
Paying user area
Try for free
Zoetis Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Zoetis Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Zoetis Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income attributable to Zoetis1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2015 | = | ÷ | = | ÷ | |||||||
| Mar 26, 2014 | = | ÷ | = | ÷ | |||||||
| Mar 28, 2013 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Zoetis Inc. Annual Report.
- Share price
- The share price demonstrates a generally upward trend over the period from 2013 to 2024. It started at $33.40 in 2013, experienced some fluctuations in the earlier years, declining slightly to $29.21 in 2014 and then rising to $46.09 in 2015. From 2016 onwards, there is a more pronounced upward trajectory, peaking at $197.76 in 2022 before a slight decline to $171.90 in 2023 and modest recovery to $183.49 in 2024.
- Earnings per share (EPS)
- EPS values display overall growth with some variability. Beginning at $0.87 in 2013, earnings per share increased steadily, despite a dip to $0.68 in 2016. From that point forward, EPS rose significantly reaching $5.12 by 2024. This marks a considerable improvement in profitability over the period.
- Price-to-Earnings Ratio (P/E)
- The P/E ratio fluctuated substantially over the years. Initial values showed a decline from 38.3 in 2013 to 29.02 in 2014, followed by an increase to 62.14 in 2016, reflecting a period of share price gains outpacing earnings growth or market expectations of future growth. Subsequent years exhibit variability between roughly 28.68 and 48.25. Notably, the P/E decreased steadily from a high of 45.82 in 2022 to 35.84 by 2024, suggesting a possible market reassessment of valuation relative to earnings growth.
Comparison to Competitors
Zoetis Inc., P/E, long-term trends, comparison to competitors
| Zoetis Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2024 | |||||||||||||
| Feb 14, 2023 | |||||||||||||
| Feb 15, 2022 | |||||||||||||
| Feb 16, 2021 | |||||||||||||
| Feb 13, 2020 | |||||||||||||
| Feb 14, 2019 | |||||||||||||
| Feb 15, 2018 | |||||||||||||
| Feb 16, 2017 | |||||||||||||
| Feb 24, 2016 | |||||||||||||
| Feb 27, 2015 | |||||||||||||
| Mar 26, 2014 | |||||||||||||
| Mar 28, 2013 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Zoetis Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Zoetis Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 13, 2024 | ||
| Feb 14, 2023 | ||
| Feb 15, 2022 | ||
| Feb 16, 2021 | ||
| Feb 13, 2020 | ||
| Feb 14, 2019 | ||
| Feb 15, 2018 | ||
| Feb 16, 2017 | ||
| Feb 24, 2016 | ||
| Feb 27, 2015 | ||
| Mar 26, 2014 | ||
| Mar 28, 2013 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Industry (Health Care)
Zoetis Inc., P/E, long-term trends, comparison to industry (health care)
| Zoetis Inc. | Health Care | |
|---|---|---|
| Feb 13, 2024 | ||
| Feb 14, 2023 | ||
| Feb 15, 2022 | ||
| Feb 16, 2021 | ||
| Feb 13, 2020 | ||
| Feb 14, 2019 | ||
| Feb 15, 2018 | ||
| Feb 16, 2017 | ||
| Feb 24, 2016 | ||
| Feb 27, 2015 | ||
| Mar 26, 2014 | ||
| Mar 28, 2013 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).